AOD-9604 vs Tirzepatide
Independent, side-by-side comparison of AOD-9604 and Tirzepatide: mechanism, half-life, dose range, safety profile, and live vendor pricing. Updated continuously as new research and listings land.
Live price snapshot
AOD-9604
Tirzepatide
AOD-9604
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence:…
Live lowest price: $34.99 across 3 vendors
Full AOD-9604 profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Live lowest price: $49.00 across 16 vendors
Full Tirzepatide profileSide-by-side comparison
| Attribute | AOD-9604 | Tirzepatide |
|---|---|---|
| Category | Metabolic & Weight Loss | Metabolic & Weight Loss |
| Research Stage | Phase II | FDA Approved |
| Mechanism of Action | AOD-9604's claimed mechanism is lipolysis (fat breakdown) via a C-terminal hGH-fragment-specific pathway distinct from classical growth hormone receptor signaling, though the mechanistic details remain incompletely characterized and contested. The "Lipolytic… | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… |
| Half-Life | ~30–60 minutes | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification |
| Typical Dose Range | 250–600 mcg per injection | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose |
| Dosing Frequency | Once daily, typically morning fasted | Once weekly subcutaneous injection |
| Administration | Subcutaneous, Oral | Subcutaneous (weekly) |
| Side Effects | AOD-9604's side effect profile is largely benign based on clinical trial data, reflecting its failure to produce significant physiological effects — a drug that does little tends to cause few side effects. From Phase 2B Clinical Trial (Heffernan 2008): In the… | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. |
| Molecular Weight | 1817.1 Da | 4813.5 Da |
| Common Vial Sizes | 2mg, 5mg | 5mg, 10mg, 15mg |
Price History
4 data points- Unknown
- Nova Peptides
- VANDL Labs
- Ion Peptide
Price History
4 data points- OF
- Unknown
- Nova Peptides
- VANDL Labs
- Ion Peptide
AOD-9604 — potential benefits
- Fat loss
- Metabolic improvement
- Joint repair (proposed)
- No insulin resistance
- No IGF-1 effects
Tirzepatide — potential benefits
- Mean body weight reduction of 22.5% at 72 weeks — highest of any anti-obesity medication (PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.58% from baseline) (PMID: 36519860)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
Frequently asked
What's the difference between AOD-9604 and Tirzepatide?
AOD-9604 is a metabolic & weight loss that aod-9604's claimed mechanism is lipolysis (fat breakdown) via a c-terminal hgh-fragment-specific pathway distinct from classical growth hormone receptor signaling, though the…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (~30–60 minutes vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, AOD-9604 or Tirzepatide?
AOD-9604 has a half-life of ~30–60 minutes. Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, AOD-9604 or Tirzepatide?
Current lowest live price on BodyHackGuide: AOD-9604 from $34.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently — see the compare tables on each compound page for the current set of offers.
Can you stack AOD-9604 and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. AOD-9604 and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Live listings from the vendors we track, refreshed continuously.
Related comparisons
Research use only. BodyHackGuide is an independent research reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks — this never affects the data or pricing shown. See editorial standards and affiliate disclosure.